Arthur T. Porter

Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92–02

Gerald E. Hanks, Thomas F. Pajak, Arthur T. Porter et al. · Journal of Clinical Oncology · 2003 · 691 citations

Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer

Eric M. Horwitz, Kyounghwa Bae, Gerald E. Hanks et al. · Journal of Clinical Oncology · 2008 · 683 citations · Full text

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.

Miljenko V. Pilepich, Richard Caplan, Roger W. Byhardt et al. · Journal of Clinical Oncology · 1997 · 609 citations

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer

Arthur T. Porter, Alexander McEwan, John Powe et al. · International Journal of Radiation Oncology*Biology*Physics · 1993 · 531 citations

Urology, Strontium-89 Adjuvant, Radiation Therapy +6

Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of rtog protocol 85-12

William Tester, Arthur T. Porter, Sucha O. Asbell et al. · International Journal of Radiation Oncology*Biology*Physics · 1993 · 281 citations

Urology, Surgical Oncology, Possible Organ Preservation +7